Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution
| Autor: | Yukiko Tadokoro, K. Takahashi, Tomomi Hayashi, Seiichirou Nishimura, Junichiro Watanabe |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Receptor ErbB-2 medicine.drug_class medicine.medical_treatment Estrogen receptor Breast Neoplasms Systemic therapy Disease-Free Survival Metastasis 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Neoplasm Metastasis Prospective cohort study Aged Chemotherapy business.industry Liver Neoplasms Estrogen Receptor alpha Middle Aged medicine.disease Metastatic breast cancer 030104 developmental biology Estrogen 030220 oncology & carcinogenesis Female Receptors Progesterone business |
| Zdroj: | Breast Cancer Research and Treatment. 166:911-917 |
| ISSN: | 1573-7217 0167-6806 |
| DOI: | 10.1007/s10549-017-4478-z |
| Popis: | In the management of estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer (ER+HER2−MBC) patients, endocrine therapy (ET) is preferred to chemotherapy (CT) as a primary systemic therapy (PST) when tumor burden is not high. However, there are no definite criteria for choosing a PST, transitioning from ET to CT or using maintenance ET subsequent to CT. We reviewed the medical records of 311 ER+HER2−MBC patients who underwent CT from September 2002 to December 2016 and assessed their outcomes. Of the 311 patients, 178 (57%) received ET as a PST (ET-first group), and 133 (43%) received CT prior to ET (CT-first group). The ET-first group showed a median overall survival (OS) from the diagnosis of MBC (OSMBC) of 1593 days, and the median OS from the initiation of CT (OSCT) was 938 days. Patients with visceral involvement, liver metastasis, soft tissue metastasis, ≥3 organ involvement, or primary advanced BC at the MBC diagnosis showed a significantly higher tendency to be assigned to the CT-first group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink